Bibliografía
1. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med 2005; 353:2462–76. https://doi.org/10.1056/NEJMoa050516
2. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: The ACCENT I randomised trial. Lancet 2002; 359:1541–9. https://doi.org/10.1016/S0140-6736(02)08512-4
3. Ford AC, Sandborn WJ, Khan KJ, et al. Efficacy of Biological Therapies in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis. Am J Gastroenterol 2011; 106:644–59. https://doi.org/10.1038/ajg.2011.73
4. Papamichael K, Cheifetz AS, Melmed GY, et al. Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol 2019; 17:1655-68. https://doi.org/10.1016/j.cgh.2019.03.037
5. Beltrán B, Iborra M, Sáez-González E, et al. Fecal Calprotectin Pretreatment and Induction Infliximab Levels for Prediction of Primary Nonresponse to Infliximab Therapy in Crohn’s Disease. Dig Dis 2019; 37:108–15. https://doi.org/10.1159/000492626
6. Zhang QW, Shen J, Zheng Q, Ran ZH. Loss of response to scheduled infliximab therapy for Crohn’s disease in adults: A systematic review and meta-analysis. J. Dig. Dis 2019; 20:65–72. DOI: 10.1111/1751-2980.12698.
7. Vande Casteele N, Ferrante M, Van Assche G, et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology 2015; 148:1320-9. https://doi.org/10.1053/j.gastro.2015.02.031
8. Steenholdt C, Brynskov J, Thomsen OO, et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: A randomised, controlled trial. Gut 2014; 63:919–27. https://doi.org/10.1136/gutjnl-2013-305279
9. Brandse JF, Mathôt RA, Kleij D Van Der, et al. Pharmacokinetic Features and Presence of Antidrug Antibodies Associate With Response to Infliximab Induction Therapy in Patients With Moderate to Severe Ulcerative Colitis. Clin Gastroenterol Hepatol 2019; 14:251-8. https://doi.org/10.1016/j.cgh.2015.10.029
10. Brandse JF, Brink GR Van Den, Wildenberg ME, et al. Loss of In fl iximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis. Gastroenterology 2015; 149:350-5 https://doi.org/10.1053/j.gastro.2015.04.016
11. Fasanmade AA, Adedokun OJ, Blank M, et al. Pharmacokinetic Properties of Infliximab in Children and Adults with Crohn’s Disease: A Retrospective Analysis of Data from 2 Phase III Clinical Trials. Clin Ther 2011; 33:946–64. https://doi.org/10.1016/j.clinthera.2011.06.002
12. Flamant M, Roblin X. Inflammatory bowel disease: towards a personalized medicine. Therap Adv Gastroenterol 2018; 11: 1-15. https://doi.org/10.1177/1756283X17745029
13. Kampa KC, Morsoletto DBG, Loures MR, et al. Importance of measuring levels of infliximab in patients treating inflammatory bowel disease in a Brazilian cohort. Arq Gastroenterol 2017; 54:333–7. https://doi.org/10.1590/s0004-2803.201700000-41
14. Hoeve K van, Dreesen E, Hoffman I, et al. Adequate Infliximab Exposure During Induction Predicts. J Pediatr Gastroenterol Nutr 2019; 68:847–53. https://doi.org/DOI: 10.1097/MPG.0000000000002265
15. Davidov Y, Ungar B, Bar-Yoseph H, et al. Association of Induction Infliximab Levels With Clinical Response in Perianal Crohn’s Disease. J Crohns Colitis 2017; 11:549–55. https://doi.org/10.1093/ecco-jcc/jjw182
16. Dreesen E, Faelens R, Van Assche G, et al. Optimising infliximab induction dosing for patients with ulcerative colitis. Br J Clin Pharmacol 2019; 85:782–95. https://doi.org/10.1111/bcp.13859
17. Papamichael K, Stappen T Van, Casteele N Vande, et al. Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol 2016; 14:543–9. https://doi.org/10.1016/j.cgh.2015.11.014
18. Papamichael K, Casteele N Vande, Ferrante M, et al. Therapeutic Drug Monitoring during Induction of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: Defining a Therapeutic Drug Window. Inflamm. Bowel Dis. 2017; 23:1510–5
19. Santacana E, Rodríguez-Alonso L, Padullés A, et al. External Evaluation of Population Pharmacokinetic Models of Infliximab in Patients With Inflammatory Bowel Disease. Ther Drug Monit 2018; 40:120–9. https://doi.org/10.1097/FTD.0000000000000476
20. Martínez-Romero GJ, Alvariño A, Hinojosa E, et al. Validation of a population pharmacokinetic model of adalimumab in a cohort of patients with inflammatory bowel disease. Rev Esp Enferm Dig 2019; 111:431-6 https://doi.org/10.17235/reed.2019.5600/2018
21. Sparrow MP, Papamichael K, Ward MG, et al. Therapeutic Drug Monitoring of Biologics During Induction to Prevent Primary Non-Response. J Crohn’s Colitis 2019. https://doi: 10.1093/ecco-jcc/jjz162. [Epub ahead of print]
22. Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006; 55:749–53. https://doi.org/10.1136/gut.2005.082909
23. Mitrev N, Vande Casteele N, Seow CH, et al. Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases. Aliment Pharmacol Ther 2017; 46:1037–53. https://doi.org/10.1111/apt.14368
24. Huang VW, Prosser C, Kroeker KI, et al. Knowledge of fecal calprotectin and infliximab trough levels alters clinical decision-making for IBD outpatients on maintenance infliximab therapy. Inflamm Bowel Dis 2015; 21:1359–67. https://doi.org/10.1097/MIB.0000000000000376
25. DʼHaens G, Ferrante M, Vermeire S, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis 2012; 18:2218–24. https://doi.org/10.1002/ibd.22917
26. Bar-Yoseph H, Levhar N, Selinger L, et al. Early drug and anti-infliximab antibody levels for prediction of primary nonresponse to infliximab therapy. Aliment Pharmacol Ther 2018; 47:212–8. https://doi.org/10.1111/apt.14410
27. Kobayashi T, Suzuki Y, Motoya S, et al. First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis—results from a multicenter prospective randomized controlled trial and its post hoc analysis. J Gastroenterol 2016; 51:241–51. https://doi.org/10.1007/s00535-015-1102-z
28. Lega S, Phan BL, Rosenthal CJ, et al. Proactively Optimized Infliximab Monotherapy Is as Effective as Combination Therapy in IBD. Inflamm Bowel Dis 2019; 25:134–41. https://doi.org/10.1093/ibd/izy203
29. Tighe D, Smith S, O’Connor A, et al. Positive relationship between infliximab and adalimumab trough levels at completion of induction therapy with clinical response rates, at a tertiary referral center. JGH Open 2017; 1:4–10. https://doi.org/10.1002/jgh3.12000
30. Kennedy NA, Heap GA, Green HD, et al. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn’s disease: a prospective, multicentre, cohort study. Lancet Gastroenterol Hepatol 2019; 4:341–53. https://doi.org/10.1016/S2468-1253(19)30012-3
31. Dotan I, Ron Y, Yanai H, et al. Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease: a population pharmacokinetic study. Inflamm Bowel Dis 2014; 20:2247–59. https://doi.org/10.1097/MIB.0000000000000212
32. Kheir N, Awaisu A, Gad H, et al. Clinical pharmacokinetics: perceptions of hospital pharmacists in Qatar about how it was taught and how it is applied. Int J Clin Pharm 2015; 37:1180–7. https://doi.org/10.1007/s11096-015-0183-3
33. Frymoyer A, Hoekman DR, Piester TL, et al. Application of Population Pharmacokinetic Modeling for Individualized Infliximab Dosing Strategies in Crohn Disease. J Pediatr Gastroenterol Nutr 2017; 65:639–45. https://doi.org/10.1097/MPG.0000000000001620
34. Raimundo Fernandes S, Bernardo S, Simões C, et al. Proactive infliximab drug monitoring is superior to conventional management in inflammatory bowel disease. J Crohn’s Colitis 2019. https://doi: 10.1093/ibd/izz131. [Epub ahead of print].
35. Feuerstein JD, Nguyen GC, Kupfer SS, et al. American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease. Gastroenterology 2017; 153:827–34. https://doi.org/10.1053/j.gastro.2017.07.032